Sab Biotherapeutics Inc. Class WSABSWPreferred / convertible
13F holders, Q1 2026 (March 31)6holders −1
1new positions
2sold out
$0.03avg. 13F price*
At the end of Q1 2026, 6 institutions reported holding Sab Biotherapeutics Inc. Class W (SABSW) in their 13F filings, down 1 from Q4 2025. 1 opened new positions and 2 sold out. The largest holders were LMR Partners LLP ($14K), Morgan Stanley ($4K) and Clear Street Group Inc. ($2K).
- Company
- Sab Biotherapeutics Inc. Class W
- CUSIP
- 78397T111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $14K |
| Exits | 2 | $36 |
All 13F filers, Q4 2025 → Q1 2026: 539,588 shares bought and 3,372 shares sold, net +536,216 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| LMR Partners LLP | — | New | 539,588 | $14K |
| Morgan Stanley | — | No change | 146,439 | $4K |
| Clear Street Group Inc. | — | Reduce -0.1% | 78,733 | $2K |
| GTS Securities LLC | — | Reduce -0.2% | 41,001 | $1K |
| UBS Group AG | — | Reduce -32.3% | 4,186 | $105 |
| Wolverine Asset Management LLC | — | No change | 1,811 | $47 |
"% of holder's portfolio" is SABSW's weight in each manager's 13F, not the share of Sab Biotherapeutics Inc. Class W the manager owns.